NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,893.58 mln
Float53.13 mln
Earnings Date07/30/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-0.54
Highly suspicious
1-Year Forecast
40.75
Attractive
Relative Strength
96
/ 100
Top performer
Debt / Equity
0.01
Debt-free
ROE
-27.28
Deeply negative
Business Description
Agios Pharmaceuticals is a US-based drug development company focused on treating blood disorders by targeting how cells produce and use energy. Its main product, PYRUKYND, is approved for adults with pyruvate kinase deficiency and is being tested for sickle cell disease and use in children, while a related treatment called AQVESME addresses a range of thalassemia conditions. The company also has several other therapies in development targeting rare blood and genetic disorders. Founded in 2007 and based in Cambridge, Massachusetts, Agios continues to build a pipeline aimed at diseases with limited existing treatment options.
